SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Noven Pharmaceuticals (NOVN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tktom who wrote (42)5/5/1999 4:44:00 PM
From: zizzerzazzer  Read Replies (1) of 66
 
Noven's teleconference held this morning can be replayed between now and May 7th by dialing 800-475-6701 and entering access code 447692. Some of the more interesting points were as follows:
1) Transdermal competition for combipatch is at least one year away, 2)Vivelle-Dot launch will be very soon, 3) Noven will be making a presentation at the Dillon Read Specialty Pharmaceutical Conference on May 26 in New York, 4)CNS Patch (I'm assuming Central Nervous System Patch) is moving along nicely and should be "unveiled" in 4 - 6 weeks.

One of the four analysts noted that NOVN was already at 40% of the consensus estimate of $0.08 per share for 1999 and asked if the company would comment. Response was that NOVN does not issue earnings forecasts but that with continued growth of Combipatch and the launch of Vivelle-Dot that NOVN expects a very good year.

Anyone else pick up on any other significant points.

Any comments on today's trading. Up only 1/32nd on five times normal volume with little or no trading in the last hour.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News